FDA Proposes New Policies to Modernize, Improve Quality of Mammography Screenings

FDA Proposes New Policies to Modernize, Improve Quality of Mammography Screenings
The U.S. Food and Drug Administration (FDA) has proposed a set of new policies to modernize and improve the quality of mammography screenings for breast cancer. The federal agency is confident that such measures may help women facing the disease make informed decisions about their health care. The immediate actions proposed by the FDA aim to improve two critical aspects. The first is to expand the information mammography facilities provide to patients and physicians to promote properly informed medical decisions; the second is to modernize mammography screening procedures to improve quality and safety standards. The new policies will amend the ones issued under the Mammography Quality Standards Act of 1992 (MQSA), which were approved by Congress to ensure high quality mammography screenings for early breast cancer detection. "Breast cancer is one of the most worrisome health concerns facing women. The FDA plays a unique and meaningful role in the delivery of quality mammography to help patients get accurate screening to identify breast health problems early, when they can be effectively addressed," FDA Commissioner Scott Gottlieb, MD, said in a press release. "As part of our overall commitment to protecting the health of women, we’re proposing new policies to modernize our oversight of mammography services by capitalizing on a number of important advances in mammography, like the increased use of 3-D digital screening tools and the need for more uniform breast density reporting. We’re committed to making sure patients have access to high-quality mammography. Today’s proposed rule would help to ensure patients continue to benefit from advances in new tools and robust oversight of this field," he said. Some of the specific measures proposed to attain
Subscribe or to access all post and page content.